基于贝叶斯给药的英夫利西单抗优化在炎症性肠病中的短期疗效
本研究为单中心前瞻性一组前后对照设计,纳入108例接受模型化给药维持治疗的成人炎症性肠病患者,评估治疗药物监测联合贝叶斯预测对临床应答的影响。结果显示,干预后总体临床缓解率从65.7%升至80.4%,中位谷浓度从3.21 mg/L升至5.13 mg/L,差异均有统计学意义。
要点
- 贝叶斯优化给药可提高炎症性肠病患者的英夫利西单抗短期临床缓解率。
- 强化治疗组缓解率从35.3%升至61.8%,缓解或轻度症状比例从76.5%升至94.1%。
- 减量组无患者Harvey-Bradshaw指数或部分Mayo评分升高,均维持谷浓度>5 mg/L。
核心结论
- 在炎症性肠病患者队列中,基于贝叶斯的优化给药改善了英夫利西单抗治疗的短期疗效。
研究设计与样本
- 单中心前瞻性研究,采用一组前后对照设计,纳入108例接受英夫利西单抗维持治疗模型化给药的成人炎症性肠病患者。
主要发现
- 初始方案维持不变者49例(45.4%),调整者59例(54.6%),其中强化34例、减量9例、停药或换药16例。
- 干预至指标测量的中位时间为126(103-160)天。
- 总体临床缓解比例从65.7%升至80.4%(P < .0001),中位英夫利西单抗谷浓度从3.21(0.99-5.45)mg/L升至5.13 mg/L(3.57-6.53)(P < .0001)。
- 强化组缓解率从35.3%升至61.8%(P = .001),临床缓解或轻度症状比例从76.5%升至94.1%。
- 减量组无患者Harvey-Bradshaw指数或部分Mayo评分升高,所有患者维持英夫利西单抗谷浓度>5 mg/L。
临床怎么用
- 对炎症性肠病维持治疗患者,可考虑采用治疗药物监测联合贝叶斯预测调整英夫利西单抗剂量以改善短期临床应答。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Therapeutic drug monitoring of infliximab can guide clinical decisions in patients with loss of response and in those who can benefit from a de-intensification. The aim of this study was to determine the impact of therapeutic drug monitoring combined with Bayesian forecasting methodology on clinical response in a real-world dataset of patients suffering from inflammatory bowel disease. METHODS: We performed a single-centre prospective study with one-group pre-test/post-test design in 108 adult inflammatory bowel disease patients treated with model-based dosing of infliximab maintenance treatment. We recorded clinical activity scores (Harvey-Bradshaw index and partial Mayo) and inflammatory biomarkers per patient. RESULTS: The initial infliximab regimen was maintained in 49 (45.4%) patients and was adjusted in 59 (54.6%) patients (34 treatment intensifications, 9 de-intensifications and 16 treatment discontinuations or therapy replacements). The median time from intervention to index measurement was 126 (103-160) days. The overall proportion of patients in clinical remission increased from 65.7% to 80.4% (P < .0001) and the median infliximab trough concentrations increased from 3.21 (0.99-5.45) to 5.13 mg/L (3.57-6.53) (P < .0001). In the intensified group, the remission rate increased from 35.3% to 61.8% (P = .001) and the percentage of patients in clinical remission or with mild symptoms increased from 76.5% to 94.1%. In the de-intensification cohort, no patients experienced an increase in the Harvey-Bradshaw index or partial Mayo scores, and all patients maintained an infliximab trough concentration of >5 mg/L. CONCLUSION: In our cohort of inflammatory bowel disease patients, Bayes-based optimized dosing improved the short-term efficacy of infliximab treatment.
引用
- Santacana Juncosa E, Rodríguez-Alonso L, Padullés Zamora A, et al. Bayes-based dosing of infliximab in inflammatory bowel diseases: Short-term efficacy. Br J Clin Pharmacol. 2020. PMID: 32495380. doi:10.1111/bcp.14410
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。